Abstract
Background
Infantile nephropathic cystinosis (INC) is a rare lysosomal storage disorder, mostly and often firstly affecting the kidneys, together with impaired disharmonious growth and rickets, eventually resulting in progressive chronic kidney disease (CKD). With the introduction of cysteamine therapy, most pediatric patients reach adulthood with no need for kidney replacement therapy. Still, detailed changes in INC patients’ clinical and morphological presentation over the past decades have not yet been thoroughly investigated.
Methods
Two groups with a respective total of 64 children with INC and 302 children with CKD, both treated conservatively and aged 2 to 18 years, were prospectively observed in the time span from 1998 to 2022 with 1186 combined annual clinical and morphological examinations clustered into two measurement periods (1998 to 2015 and ≥ 2016).
Results
In INC patients, thoracic proportion indices remained markedly increased, whereas body fat stores remained decreased over the past 25 years (+ 1 vs. below ± 0 z-score, respectively). Their CKD peers presented with overall improved growth, general harmonization of body proportions, and improved body fat stores, while INC patients only presented with an isolated significant increase in leg length over time (∆0.36 z-score). eGFR adjusted for age did not significantly change over the past 25 years in both groups. Alkaline phosphatase (ALP) showed a significant decrease in CKD patients over time, while remaining above normal levels in INC patients.
Conclusions
Disproportionate thoracic shape and impaired body fat stores remain the most characteristic morphological traits in INC patients over the past 25 years, while causal mechanisms remain unclear.
Graphical Abstract
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Infantile nephropathic cystinosis (INC) is a rare lysosomal storage disorder with multisystem implications caused by intracellular accumulation of cystine crystals [1, 2]. The aggregation of crystals in internal organs was first described in 1903 by Kaufmann, which were later classified as cystine crystals by Abderhalden [3], and usually firstly results in generalized proximal tubule dysfunction (De Toni–Debré–Fanconi syndrome) thus causing symptoms such as polyuria and failure to thrive as well as electrolyte imbalances [1, 4, 5]. The disease typically manifests within the first 18 months of life and results in progressive chronic kidney disease (CKD) with numerous other complications such as malnutrition [6], hypophosphatemic rickets, myopathy [7], corneal deposits [8], and central nervous system complications [9], generally followed by kidney failure at around 10 years if not causally treated [10, 11]. Due to advances in dialysis therapy and graft surgery in the 1970s [12], progressive kidney failure did not necessarily result in death anymore but was alleviated by use of procedures replacing impaired kidney function. This was further enhanced in 1997 with the introduction of cystine-depleting therapy in Europe which prolonged the pre-terminal period, delayed the onset of complications, and increased life expectancy [13, 14]. To date, INC patients present with characteristic impairments in body growth and composition, i.e., disproportionate short stature with short legs and increased chest depth and reduced body fat [15, 16]. However, the dynamic changes in body morphology of INC children over the past decades remain largely unknown. To address these gaps, anthropometric parameters and their associations with clinical parameters were assessed in 64 children with INC and 302 CKD peers to facilitate a detailed insight into the disease and how its clinical and morphological appearance has shifted over the past 25 years.
Material and methods
Study design and patients
The prospective observational cohort study “CKD growth and development” was initiated in May 1998 at the Department of Pediatric Nephrology, Charité-Universitätsmedizin Berlin, Berlin, Germany, and expanded in the year 2000 to Hannover Medical School, Hannover, Germany, where in 2016 the complementing prospective multicenter cohort study “Growth and cognitive-motor abilities in children with nephropathic cystinosis and chronic kidney disease” commenced. CKD controls continued to be measured and examined at Hannover Medical School whereas patients with INC were also measured in nine additional German hospitals as well as two centers in Austria. For the analysis of treatment initiation and age at diagnosis, all children with INC (N = 88) were assessed. From this overall sample of INC and CKD patients with CKD stages 1–5 prior to kidney replacement therapy (KRT) [17], patients with acquired causes of CKD (e.g., hemolytic uremic syndrome) and/or complex multi systemic diseases (e.g., Bartter or Denys-Drash syndrome) with a possible secondary impact on growth and development were excluded. The decision to solely include conservatively treated children in this presented analysis is based on findings showing that INC patients treated early and adequately with cysteamine require KRT less frequently today, making conservative treatment of most research interest [13]. In total, 64 children with INC (32 male 32 female) and 302 with CKD (185 male 117 female) due to other congenital or hereditary kidney diseases (CKD controls) were eligible for this analysis. Patients were aged between 2 and 18 years and underwent 1186 annual measurements (INC, 193; CKD, 993) with an average of 3.24 annual measurements per patient (INC, 3.02; CKD, 3.29). INC and CKD patients’ measurements were divided into two measuring periods (clusters): the first ranging from May 1998 to December 2015 (1998–2015) and the second ranging from January 2016 to December 2022 (≥ 2016). These clusters were chosen to best depict changes between the two periods with varied medication and therapy options and to compare children treated and diagnosed early with those who were diagnosed much later. All INC patients within this study received cysteamine treatment. Clinical appointments included monitoring of biochemical parameters as well as individual medication, physical examinations, and anthropometric measurements. Approval by the ethics committee was obtained from the institutional review boards at each study site. The study was performed in accordance with the Declaration of Helsinki. All parents/guardians gave their written consent as well as patients where age appropriate.
Methods
Standard laboratory techniques were used for determination of blood/serum levels of hemoglobin, albumin, creatinine, potassium, calcium, phosphate, alkaline phosphatase (ALP), and parathyroid hormone (PTH). Rates of anemia, hypokalemia, hypophosphatemia, and hypocalcemia were calculated using age- and sex-dependent reference intervals [17,18,19]. Serum calcium was corrected for serum albumin [20]. Metabolic acidosis was defined as a serum bicarbonate < 22 mmol/L [18, 19]. Estimated glomerular filtration rate (eGFR) was calculated based on the revised Schwartz equation [21]. Analysis of leukocyte cystine content levels was not feasible due to a lack of data from earlier time points. Annual anthropometric measurements included linear (height, sitting height, leg length) and transversal (chest depth and width) body dimensions and upper arm skin folds, while body mass index (BMI), sitting height index (ratio of sitting to total body height), upper arm fat area (UFA), and thoracic indices (chest depth to height ratio and chest depth to chest width ratio) were calculated as described in previous works [15, 16]. UFA and BMI were used as indirect markers of body composition. All measurements were performed by the same investigator (MZ) and taken in accordance with the International Biological Program using standardized equipment. z-scores regarding anthropometric parameters were calculated using reference data obtained from 5260 healthy children [22, 23]. All children received regular dietary counselling. Age at diagnosis and therapy initiation was collected from patients’ personal health records, while age at menarche was documented in female patients during examinations.
Statistical analysis
This study expands upon a previously published study within this project which was initiated in 2016 [15, 16]. Descriptive statistics are given in terms of mean and standard deviation or estimated marginal mean (Est. MM) and 95% confidence interval (for repeated measurements), or median with interquartile range (IQR), or incidence percentage (%), as suitable for measurement scale/model and normality of distribution. Distribution normality was evaluated by using the Shapiro–Wilk test. To compare two groups of independent measurements either the Mann–Whitney test or t-test was used, as appropriate. To test differences between incidences of clinical and characteristics of medication in the two measurement clusters (1998–2015 vs. ≥ 2016) within the INC and CKD groups, chi-square test was used (MedCalc Software Ltd. version 22.014). Linear mixed-effect models (LMM) (repeated measurements with setting intercept and subject ID as random effect) were used to test differences in clinical/biochemical indicators between the two measurement clusters in INC and CKD patients with various numbers of measurements as well as varying time gaps amid measurements. Associations of anthropometric (leg length, anterior–posterior chest (APC) height ratio, and upper arm fat area) and clinical/biochemical characteristics (covariates: age, eGFR, serum bicarbonate, hemoglobin, sodium, potassium, calcium, phosphate, ALP, PTH) were also analyzed by use of LMM by setting the intercept and subject ID as random effect with unstructured covariance matrix type (UN). In the aforementioned LMM analysis, information criteria were used to choose the most appropriate model for each analysis and parameter group. Additionally, as mean age varied significantly between the two clusters, we analyzed biochemical parameters separately between the two clusters for INC and CKD patients by using LMM adjusted for age. Results were considered significant at a level of p < 0.05. SPSS for Windows, version 28.0 (IBM Corporation, NY, USA), was used. Graphs were generated by use of GraphPad Prism 9.3.1 (GraphPad Software, Inc., San Diego, CA).
Results
Patient characteristics and biochemical parameters
Patient characteristics, as well as clinical and biochemical parameters, are presented in Tables 1 and 2. When analyzing the entire INC sample (all measurements from 1998 to 2022, regardless of KRT status, and with birth decades ranging from 1980 to 2010s), age at diagnosis (median 2.50 (IQR 1.8, 3.6) to 0.95 years (IQR 0.6, 2.4)) as well as age at initiation of cysteamine therapy (median 4.28 (IQR 2.3, 9.5) to 1.10 years (IQR 0.7, 2.4)) decreased significantly from birth decade 1980 to decade 2010 (both p < 0.05, Fig. 1). Narrowing in from this broader patient cohort, we further analyzed solely conservatively treated patients as described in the methods. Comparing the two measurement clusters (1998–2015 vs. ≥ 2016), patient age (at measurement) increased significantly in the INC group from 6.31 years to 11.10 years and in the CKD group from 8.76 years to 12.28 years (both p < 0.001, Table 1). Within each respective cluster, INC and CKD patients were comparable with regard to age distribution at measurement. With regard to distribution of sex, INC and CKD controls did not differ significantly in both measurement clusters. Congenital causes of CKD within the observed CKD patients were increased in the measurement cluster after 2015 (78.0% vs. 90.7%, p < 0.01). Raw eGFR declined significantly in both groups over time, but when adjusted for age, no significant change was observed (Table 1). Although administration of erythropoietin therapy decreased in both groups (only significantly in the CKD group), the incidence of anemia declined significantly in both groups over time (Table 2). A significant increase in hypokalemia rates in the INC group (34.1 to 50.0%, p < 0.05) was observed from first to second measurement cluster, whereas CKD patients presented with respectively generally lower and decreasing rates (9.8 to 3.4%, p < 0.01). ALP levels significantly declined in the CKD group from first to second measurement cluster. In the INC group, ALP z-scores remained elevated above normal across the observed time frame (Table 1). The administration of calcium and calcitriol therapy markedly decreased over time in patients with CKD. The administration of growth hormone treatment declined in both groups when compared to the earlier measurement cluster, but not significantly (INC 52.1 to 50.0%, CKD 30.6 to 27.5%, both p > 0.05, Table 2). In the period after 2015, both INC and CKD patients received vitamin D (primarily in the form of cholecalciferol) and phosphate therapy significantly more often than in the preceding measurement cluster (Table 2). From 1998 to 2015, all INC patients were treated with immediate release (IR) cysteamine at mean doses of 1179.10 mg/m2 body surface area (95% CI 1048.56–1309.62), of which two patients switched to delayed release (DR) cysteamine by 2015. In the subsequent measurement cluster, the majority of patients were switched to DR cysteamine or were started on DR cysteamine from the beginning, which was given at mean doses of 1074.38 mg/m2 body surface area (95% CI 925.80–1223.00).
Anthropometric characteristics
Linear growth of INC and CKD patients is presented in Fig. 2 and shows major impairment in all parameters in children with INC over the course of the two measurement clusters. INC and CKD patients presented with similar linear body pattern in the first measuring cluster, with sitting height as the best preserved parameter (INC − 1.69, CKD − 1.03 z-score) and overall short stature (INC − 2.22, CKD − 1.44 z-score) as a result of markedly impaired leg length (INC − 2.12, CKD − 1.42 z-score). In the second cluster, CKD patients presented with synchronized improvement in all three parameters (statistically significant in leg length and stature, both p < 0.01).
Contrarily, INC patients exhibited uncoupled growth dynamics in leg length and sitting height, with a significant increase in leg length from − 2.12 to − 1.76 z-score (p < 0.05) and a decrease in sitting height (− 1.69 to − 1.85 z-score), resulting in improved stature (− 2.22 to − 2.09 z-score, Fig. 2). Both latter tendencies did not reach levels of statistical significance (p > 0.05).
Concerning thoracic configurations, which are presented in Fig. 3, both APC/height ratio (2.03 vs. 1.87 z-score) and APC/transverse ratio (1.01 vs. 1.57 z-score) remained the two most markedly elevated parameters in children with INC over the complete observation period; indicating severe trunk deformation. On the other hand, their peers with CKD presented with more homogeneous z-scores of the different parameters.
In patients with INC from 1998 onwards, upper arm fat area (UFA) (− 0.48 to − 0.60 z-score) and BMI (0.05 to − 0.37 z-score) declined, though only the decline in BMI reached levels of statistical significance. Contrarily, in their peers with CKD, BMI (− 0.16 to 0.03 z-score) as well as UFA (− 0.39 to 0.08 z-score) significantly increased over the course of the two measurement clusters (Fig. 3). Accordingly, age at menarche in girls with INC increased from a mean age of 13.47 ± 2.20 to 13.81 ± 1.13 years while conversely, in the CKD group, menarcheal age declined from a mean age of 13.00 ± 1.38 to 12.03 ± 0.93 years after 2015 (Fig. 4). Both tendencies did not reach levels of statistical significance (p > 0.05).
As thoracic disproportion and impaired body fat storage were the features that most clearly distinguished INC from CKD patients, we analyzed the delta between most elevated markers of thoracic disproportion (APC/height ratio) and most decreased markers of body fat storage (UFA in INC patients and BMI in CKD patients, respectively). We found that high delta values in children with INC persisted over both measurement clusters (∆2.52 to ∆2.47 z-score), while in children with CKD, these values markedly declined (∆1.19 to ∆0.88 z-score), indicating a synchronization and harmonization of body proportions and composition in this group. The findings of persisting elevated delta values in patients with INC hint at a sustained striking disharmony of thoracic shape and body composition (Fig. 3).
Associations between leg length, APC/height ratio, UFA, and clinical/biochemical parameters
As an increase in leg length in INC patients over time was the most striking change in morphology, together with consistently reduced upper arm fat area z-scores and elevated APC/height ratios, associations between the aforementioned anthropometric parameters and clinical/biochemical parameters were analyzed using linear mixed models (Table 3). The number of significant associations between leg length and clinical parameters declined in both groups (INC and CKD) compared to the respective earlier measurement cluster, but most strikingly, UFA in INC patients was not significantly associated with any of the clinical parameters in either of the measurement clusters. Increased INC and CKD patient age associated significantly with higher leg length. This held true across both measurement clusters. In the earlier cluster, lower APC/height ratio was significantly associated with increasing age in CKD patients. In both CKD clusters, UFA was significantly positively associated with increasing age. eGFR was positively associated with leg length in both CKD measurement clusters, but only in the earlier INC measurement cluster. In CKD patients, improved kidney function was associated with improved UFA in the first cluster. Leg length was significantly positively associated with hemoglobin and phosphate levels in the earlier measurement cluster in patients with INC. CKD patients with high ALP levels exhibited improved leg length in the first cluster while increased bicarbonate was associated with impaired leg length. In the subsequent cluster, sodium was associated with impaired leg length. Regarding thoracic configuration, APC/height ratio in the INC group was significantly positively associated with bicarbonate and phosphate levels, while hemoglobin was significantly negatively associated in the first cluster. In the ensuing cluster, higher sodium levels were associated with decreased APC/height ratio in INC patients. In their peers with CKD, the only observed significant association between APC/height ratio and biochemical parameters was observed with bicarbonate which showed negative associations with APC/height ratio in the second measurement cluster. Corresponding with our findings of persisting reduced body fat stores in children with INC (Fig. 3), none of the observed clinical parameters showed any significant association in INC patients with UFA in both measurement clusters. In CKD patients, higher hemoglobin levels as well as lower sodium levels were associated with increased UFA z-scores in the second measurement cluster.
Discussion
Over the past 25 years, both INC patients and CKD patients underwent changes in their morphology and clinical presentation. However, while body morphology in patients with CKD retained homogeneity between individual parameters, children with INC retained disproportion in their thoracic shape, as well as markedly more reduced fat stores, and also exhibited striking changes in leg length over time. While those findings still show INC-specific challenges in growth and clinical development, the significant increase in mean age of conservatively treated INC patients from first to second measurement cluster (p < 0.001) illustrates the drastic improvement in prognosis in recent times and shift towards conservative treatment modalities. Furthermore, the mean age in our conservatively treated sample measured after 2015 has exceeded the former age at kidney failure described in historic works [5, 12, 24]; highlighting the dynamic shift in prognosis over past years, making it feasible and relevant to ask questions about the development of affected children into adulthood.
These findings are in accordance with studies showing that the onset of kidney failure can be delayed, and incidence of KRT in the pediatric INC cohort can be reduced by adequate treatment with cysteamine, preferably initiated in the first 5 years of life [13] or even earlier, in the first 2 years [25]. Furthermore, children who started cysteamine therapy before 2 months of age had higher mean eGFR rates at all times than their peers who started therapy later [26]. However, there seems to be no defined age and every month counts. We observed a drastic decrease in age at diagnosis, as well as age at therapy initiation from the earlier to the later measurement cluster. Furthermore, a significant approximation of these two time points occurred. This hints at improved diagnostic procedures and more immediate action in the form of cysteamine therapy commencement, which then likely contributes to the improved renal outcomes observed in patients with INC [13, 26]. This raises questions about the possible impact of early treatment on growth and morphology.
As described in recent publications, INC and CKD patients share a similar pattern of body proportions in the prepubertal period with markedly impaired leg length growth resulting in overall short stature [15, 16]. Now, we have shown that this childhood INC pattern shared with CKD peers was also the apparent morphological pattern in the earlier INC measurement cluster of this analysis, where patients were, incidentally, younger in age. Only in recent years (≥ 2016), was the morphology in INC patients first shown to deviate from this pattern, with a significant increase in leg length, resulting in noticeably increased stature compared to earlier time points (Fig. 2). Interestingly, the number of significant associations between the parameter most distinctive between both patterns, i.e. leg length, and respective clinical parameters markedly declined between time clusters (1998–2015 vs. ≥ 2016) in INC patients (Table 3). This suggests that factors exceeding the current common observational parameters of INC come into play in influencing leg length.
Another striking finding from the analysis of associations between clinical parameters and morphological characteristics was the complete absence of any associations with UFA in INC patients over both clusters. Furthermore, body fat stores and BMI declined even further over the course of the past 25 years, though only BMI did so significantly, despite the fact that all children in the study received dietary counselling to obviate malnutrition caused by an inadequate diet. Possible explanations for diminished body fat stores in the past mostly surrounded gastrointestinal causes such as vomiting and nausea [6], a now known side effect of cysteamine therapy possibly caused by the increased release of gastric acid after ingestion [27], but with the introduction of DR cysteamine, these side effects were reduced [28]. Still, it is important to note that vomiting and nausea were already observed in INC patients before the introduction of cysteamine [6], so the medication side effects may have only contributed to an already existing problem. It seems that the issue of reduced body fat amounts, a characteristic of INC patients already described in the first report dating back to the early twentieth century [3], is linked to underlying causes that remain largely uncertain.
As fat storage is closely linked to the onset of menarche and maturation [29,30,31], the further decline of UFA to − 0.60 z-score in the second cluster can be considered one possible reason for the statistically non-significant delay in onset of menarche observed in our sample (Fig. 4). These findings are in accordance with theories by Frisch and McArthur, specifying a certain percentage of total body fat required for menarche, possibly undercut in girls with INC [32].
Not only did body composition show striking irregularities in children with INC, but body proportions deviated markedly from normal levels, too. Especially, the extremely elevated ratios of thoracic depth to width and height ratios clearly distinguished INC patients from their CKD peers and are a hallmark of disease morphology, as first described by Müller et al. [16]. Furthermore, thoracic diameters have been shown to increase with age, contributing even further to thoracic deformation with a conical chest shape [16]. These morphological irregularities could restrictively impair respiratory mechanics with ensuing pulmonary insufficiency [16, 33], which has been found to affect up to 69% of adult INC patients in a study by Gahl et al. [24]. Thoracic involvement of INC regarding ribcage configuration and respiration is complicated by reports of general myocyte cystine crystal accumulation [34, 35]. These factors contribute further to the increasing demand for interdisciplinary follow-up with increased life expectancy.
Regarding significant developments in clinical parameters, specifically kidney function, our analysis showed a significant decrease in eGFR in both groups over the course of the two measurement clusters while at the same time, mean age increased significantly (Table 1). We therefore adjusted eGFR for age and found that no significant change was noticeable over the past 25 years in either INC (Est. MM 62.90 mL/min per 1.73 m2 vs. 59.35 mL/min per 1.73 m2) or in CKD patients (Est. MM 38.71 mL/min per 1.73 m2 vs. 36.82 mL/min per 1.73 m2). The relatively unchanged eGFR is in accordance with studies showing general improvement of kidney function in children with INC as well as CKD and hint at improved clinical care [13, 36].
As kidney function is intrinsically tied to bone metabolism, the persistent elevated ALP levels in INC patients over the past 25 years were striking. ALP is used as a marker for osteoblast activity and bone formation/mineralization; a process typically impaired in children with cystinosis mineral bone disease (CMBD) [37] as well as in patients with CKD mineral bone disease (CKD–MBD) [38]. This, together with our findings regarding reduced growth in the INC group, is in accordance with the known INC feature of hypophosphatemic rickets, which is normally also known to be accompanied by low PTH levels [7]. Our aforementioned results with persistent impaired growth in the second measurement cluster thus hint at a perseverance of this disease feature into recent times, despite modern treatment protocols. This characteristic may also be possibly linked to the persisting impaired thoracic shape, as children with rickets often also present with typical thoracic deformation patterns, e.g., pectus excavatum [39]. Since increased ALP levels have furthermore been shown to be associated with higher all-cause mortality and kidney failure [40] as well as increased risk of cardiovascular events [41], these elevated ALP values do not only hint at unimproved bone metabolism but they may also contribute to the cardiac problems observed in adult INC patients [24].
Our study is limited by the lack of age group–related analysis [15, 16]; however, examination by age group would have exceeded the scope of this study and not have been reflective of the general overview of the past 25 years we intend to give. Our aim is to provide a new approach to analyzing data obtained over 25 years in this prospective, multicenter observational cohort study regarding growth and development in children with INC and CKD. While CKD patients showed general improvement and harmonization in longitudinal parameters and body composition with an unchanged pattern of body morphology, INC patients presented with an isolated increase in leg length and changed body pattern over time. Trunk deformity and reduced body fat amounts have been, and remain, the most characteristic anthropometric features in INC patients over the past 25 years and seemingly unchanged despite modern treatment protocols. Our findings, particularly the lack of significant associations between assessed clinical parameters and body fat amounts, leave room for further investigation into the underlying causes and potential interventions to improve the care and quality of life of INC patients.
Data availability
The data supporting the findings of this study are available on request from the corresponding author. Data is not publicly available due to privacy or ethical restrictions.
References
Cherqui S, Courtoy PJ (2017) The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives. Nat Rev Nephrol 13:115–131. https://doi.org/10.1038/nrneph.2016.182
Nesterova G, Gahl WA (2013) Cystinosis: the evolution of a treatable disease. Pediatr Nephrol 28:51–59. https://doi.org/10.1007/s00467-012-2242-5
Abderhalden E (1903) Familiäre cystindiathese. Zeitschrift Für Physiologische. Chemie 38:557–561
Elmonem MA, Veys KR, Soliman NA, van Dyck M, van den Heuvel LP, Levtchenko E (2016) Cystinosis: a review. Orphanet J Rare Dis 11:47. https://doi.org/10.1186/s13023-016-0426-y
Gahl WA, Thoene JG, Schneider JA (2002) Cystinosis. N Engl J Med 347:111–121. https://doi.org/10.1056/NEJMra020552
Elenberg E, Norling LL, Kleinman RE, Ingelfinger JR (1998) Feeding problems in cystinosis. Pediatr Nephrol 12:365–370. https://doi.org/10.1007/s004670050467
Haffner D, Leifheit-Nestler M, Alioli C, Bacchetta J (2022) Muscle and bone impairment in infantile nephropathic cystinosis: new concepts. Cells 11:170. https://doi.org/10.3390/cells11010170
Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI (2000) Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab 71:100–120. https://doi.org/10.1006/mgme.2000.3062
Servais A, Saitovitch A, Hummel A, Boisgontier J, Scemla A, Sberro-Soussan R, Snanoudj R, Lemaitre H, Legendre C, Pontoizeau C, Antignac C, Anglicheau D, Funalot B, Boddaert N (2020) Central nervous system complications in adult cystinosis patients. J Inherit Metab Dis 43:348–356. https://doi.org/10.1002/jimd.12164
Markello TC, Bernardini IM, Gahl WA (1993) Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 328:1157–1162. https://doi.org/10.1056/NEJM199304223281604
Gahl WA, Schneider JA, Thoene JG, Chesney R (1986) Course of nephropathic cystinosis after age 10 years. J Pediatr 109:605–608. https://doi.org/10.1016/s0022-3476(86)80221-9
Goodyer P (2011) The history of cystinosis: lessons for clinical management. Int J Nephrol 2011:929456. https://doi.org/10.4061/2011/929456
Brodin-Sartorius A, Tête M, Niaudet P, Antignac C, Guest G, Ottolenghi C, Charbit M, Moyse D, Legendre C, Lesavre P, Cochat P, Servais A (2012) Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 81:179–189. https://doi.org/10.1038/ki.2011.277
European Medicines Agency (2015) EPAR summary for the public Cystagon mercaptamine. https://www.ema.europa.eu/en/documents/overview/cystagon-epar-summary-public_en.pdf. Accessed 25 January 2024
Kluck R, Müller S, Jagodzinski C, Hohenfellner K, Büscher A, Kemper MJ, Oh J, Billing H, Thumfart J, Weber LT, Acham-Roschitz B, Arbeiter K, Tönshoff B, Hagenberg M, Kanzelmeyer N, Pavičić L, Haffner D, Zivicnjak M (2022) Body growth, upper arm fat area, and clinical parameters in children with nephropathic cystinosis compared with other pediatric chronic kidney disease entities. J Inherit Metab Dis 45:192–202. https://doi.org/10.1002/jimd.12473
Müller S, Kluck R, Jagodzinski C, Brügelmann M, Hohenfellner K, Büscher A, Kemper MJ, Fröde K, Oh J, Billing H, Thumfart J, Weber LT, Acham-Roschitz B, Arbeiter K, Tönshoff B, Hagenberg M, Pavičić L, Haffner D, Zivicnjak M (2023) Chest configuration in children and adolescents with infantile nephropathic cystinosis compared with other chronic kidney disease entities and its clinical determinants. Pediatr Nephrol 38:3989–3999. https://doi.org/10.1007/s00467-023-06058-x
KDIGO (2012) Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:288–291
KDOQI (2009) Clinical practice guideline for nutrition in children with CKD: 2008 update. executive summary. Am J Kidney Dis 53:11. https://doi.org/10.1053/j.ajkd.2008.11.017
Adeli K, Higgins V, Nieuwesteeg M, Raizman JE, Chen Y, Wong SL, Blais D (2015) Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the canadian health measures survey. Clin Chem 61:1049–1062. https://doi.org/10.1373/clinchem.2015.240515
Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643–646
De Souza VC, Rabilloud M, Cochat P, Selistre L, Hadj-Aissa A, Kassai B, Ranchin B, Berg U, Herthelius M, Dubourg L (2012) Schwartz formula: is one k-coefficient adequate for all children? PLoS One 7:e53439. https://doi.org/10.1371/journal.pone.0053439
Zivicnjak M, Narancić NS, Szirovicza L, Franke D, Hrenović J, Bisof V (2003) Gender-specific growth patterns for stature, sitting height and limbs length in Croatian children and youth (3 to 18 years of age). Coll Antropol 27:321–334
Zivicnjak M, Smolej Narancic N, Szirovicza L, Franke D, Hrenovic J, Bisof V, Tomas Z, Skaric-Juric T (2008) Gender-specific growth patterns of transversal body dimensions in croatian children and youth (2 to 18 years of age). Coll Antropol 32:419–431
Gahl WA, Balog JZ, Kleta R (2007) Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med 147:242–250. https://doi.org/10.7326/0003-4819-147-4-200708210-00006
Emma F, Hoff WV, Hohenfellner K, Topaloglu R, Greco M, Ariceta G, Bettini C, Bockenhauer D, Veys K, Pape L, Hulton S, Collin S, Ozaltin F, Servais A, Deschênes G, Novo R, Bertholet-Thomas A, Oh J, Cornelissen E, Janssen M, Haffner D, Ravà L, Antignac C, Devuyst O, Niaudet P, Levtchenko E (2021) An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Kidney Int 100:1112–1123. https://doi.org/10.1016/j.kint.2021.06.019
Nießl C, Boulesteix A, Oh J, Palm K, Schlingmann P, Wygoda S, Haffner D, Wühl E, Tönshoff B, Buescher A, Billing H, Hoppe B, Zirngibl M, Kettwig M, Moeller K, Acham-Roschitz B, Arbeiter K, Bald M, Benz M, Galiano M, John-Kroegel U, Klaus G, Marx-Berger D, Moser K, Mueller D, Patzer L, Pohl M, Seitz B, Treikauskas U, von Vigier RO, Gahl WA, Hohenfellner K (2022) Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis. Mol Genet Metab 136:268–273. https://doi.org/10.1016/j.ymgme.2022.06.010
Dohil R, Newbury RO, Sellers ZM, Deutsch R, Schneider JA (2003) The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 143:224–230. https://doi.org/10.1067/S0022-3476(03)00281-6
van Stein C, Klank S, Grüneberg M, Ottolenghi C, Grebe J, Reunert J, Harms E, Marquardt T (2021) A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis. Orphanet J Rare Dis 16:387. https://doi.org/10.1186/s13023-021-01991-2
Živičnjak M, Pavicic L (1996) Variation in menarcheal age according to the growth channels appertaination and the soft tissue component in pubertal girls. Coll Antropol 20:353–363
Matkovic V, Ilich JZ, Skugor M, Badenhop NE, Goel P, Clairmont A, Klisovic D, Nahhas RW, Landoll JD (1997) Leptin is inversely related to age at menarche in human females. J Clin Endocrinol Metab 82:3239–3245. https://doi.org/10.1210/jcem.82.10.4280
Karapanou O, Papadimitriou A (2010) Determinants of menarche. Reprod Biol Endocrinol 8:115. https://doi.org/10.1186/1477-7827-8-115
Frisch RE, McArthur JW (1974) Menstrual cycles: Fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science 185:949–951. https://doi.org/10.1126/science.185.4155.949
Anikster Y, Lacbawan F, Brantly M, Gochuico BL, Avila NA, Travis W, Gahl WA (2001) Pulmonary dysfunction in adults with nephropathic cystinosis. Chest 119:394–401. https://doi.org/10.1378/chest.119.2.394
Charnas LR, Luciano CA, Dalakas M, Gilliatt RW, Bernardini I, Ishak K, Cwik VA, Fraker D, Brushart TA, Gahl WA (1994) Distal vacuolar myopathy in nephropathic cystinosis. Ann Neurol 35:181–188. https://doi.org/10.1002/ana.410350209
Sadjadi R, Sullivan S, Grant N, Thomas SE, Doyle M, Hammond C, Duong R, Corre C, David W, Eichler F (2020) Clinical myopathy in patients with nephropathic cystinosis. Muscle Nerve 61:74–80. https://doi.org/10.1002/mus.26726
Franke D, Winkel S, Gellermann J, Querfeld U, Pape L, Ehrich JHH, Haffner D, Pavičić L, Zivičnjak M (2013) Growth and maturation improvement in children on renal replacement therapy over the past 20 years. Pediatr Nephrol 28:2043–2051. https://doi.org/10.1007/s00467-013-2502-z
Hohenfellner K, Rauch F, Ariceta G, Awan A, Bacchetta J, Bergmann C, Bechtold S, Cassidy N, Deschenes G, Elenberg E, Gahl WA, Greil O, Harms E, Herzig N, Hoppe B, Koeppl C, Lewis MA, Levtchenko E, Nesterova G, Santos F, Schlingmann KP, Servais A, Soliman NA, Steidle G, Sweeney C, Treikauskas U, Topaloglu R, Tsygin A, Veys K, V Vigier R, Zustin J, Haffner D (2019) Management of bone disease in cystinosis: statement from an international conference. J Inherit Metab Dis 42:1019–1029
Bacchetta J, Schmitt CP, Bakkaloglu SA, Cleghorn S, Leifheit-Nestler M, Prytula A, Ranchin B, Schön A, Stabouli S, Van de Walle J, Vidal E, Haffner D, Shroff R (2023) Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and dialysis working groups and the pediatric renal nutrition taskforce. Pediatr Nephrol 38:3163–3181. https://doi.org/10.1007/s00467-022-05825-6
Lips P, de Jongh RT (2018) Vitamin D deficiency in immigrants. Bone Rep 9:37–41. https://doi.org/10.1016/j.bonr.2018.06.001
Taliercio JJ, Schold JD, Simon JF, Arrigain S, Tang A, Saab G, Nally JV, Navaneethan SD (2013) Prognostic importance of serum alkaline phosphatase in CKD stages 3–4 in a clinical population. Am J Kidney Dis 62:703–710. https://doi.org/10.1053/j.ajkd.2013.04.012
Liu K, Yu Y, Yuan Y, Xu X, Lei W, Niu R, Shen M, Zhou L, Peng R, Wang Q, Yang H, Guo H, Ge Y, Liu G, He M, Wu T, Zhang X (2023) Elevated levels of serum alkaline phosphatase are associated with increased risk of cardiovascular disease: a prospective cohort study. J Atheroscler Thromb 30:795–819. https://doi.org/10.5551/jat.63646
Acknowledgements
The authors sincerely thank patients, parents, doctors, and nurses from the participating centers and especially Sabine Wiedenhöft for her great contribution in organizing this study.
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was supported by a research grant from Horizon, USA, to Dieter Haffner.
Author information
Authors and Affiliations
Contributions
MZ, MB, and DH designed the study. MZ performed anthropometric measurements. KH, AB, MJK, KF, NK, JO, HB, JG, DM, LTW, BAR, KA, BT, MH, and DH were involved in recruiting patients and providing clinical data in each specific center. MB, SM, AB, and MZ collected clinical data, and MZ, MSŽ, and MB performed the statistical analysis and interpreted the data. MB, SM, AB, and MZ wrote the first draft of the manuscript. MZ and DH revised the manuscript. All authors reviewed the manuscript critically and approved the final version for publication.
Corresponding author
Ethics declarations
Ethics statement
The study received appropriate ethics committee approval from the Institutional Review Board at each site and was performed in accordance with the Declaration of Helsinki.
Patient consent statement
Written informed consent was obtained from all parents/guardians, with consent or assent from patients where age appropriate.
Competing interests
Dieter Haffner received speaker fees and research grants from Horizon and Chiesi. Jun Oh received speaker fees from Horizon and Chiesi. Burkhard Tönshoff participated in advisory boards for Chiesi. Lutz T. Weber received speaker fees from Chiesi. Katharina Hohenfellner was supported by the Cystinosis Foundation Germany. All other authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Sadly, Heiko Billing passed away before the completion of this work. Since the research was initiated with his contribution, the authors decided to submit his name as co-author.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Brügelmann, M., Müller, S., Bohlen, A.V. et al. Morphological changes and their associations with clinical parameters in children with nephropathic cystinosis and chronic kidney disease prior to kidney replacement therapy over 25 years. Pediatr Nephrol (2024). https://doi.org/10.1007/s00467-024-06421-6
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00467-024-06421-6